(PharmaNewsWire.Com, August 02, 2019 ) The increasing incidence of renal disorders, growing incidence of other chronic disorders impacting renal function, growing awareness and adoption of preventive healthcare approaches, implementation of favorable government initiatives to promote renal health, rising geriatric population.
The Creatinine Measurement market is expected to reach USD 564.5 Million by 2023 from USD 349.9 Million in 2017, at a CAGR of 8.4%.
The creatinine measurement market, by test type, is segmented into the Jaffe’s kinetic method and enzymatic method. In 2018, the Jaffe’s kinetic method segment is expected to hold the largest share of the creatinine measurement market. The widespread availability and cost-effectiveness of kits and reagents used in Jaffe’s kinetic method is a key factor driving the growth of this market.
The creatinine measurement market is segmented into blood/serum and urine samples. The blood/serum segment is expected to witness the highest CAGR over the forecast period. Most creatinine measurement kits and reagents are based on the analysis of creatinine in blood samples owing to its accuracy in inferring creatinine concentration and low risk of contamination.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
